Avalo Therapeutics (AVTX) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Avalo Therapeutics (AVTX) has outperformed Geron (GERN) over the past year, losing 5.6% versus a loss of 11.6%. Over five years, GERN leads with a -13.5% price change compared with -99.8% for AVTX. Geron is the larger company by market cap ($783.8 million vs $720.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | GERN |
|---|---|---|
| Share price | $13.43 | $1.22 |
| Market cap | $720.25M | $783.82M |
| 1-day change | -1.10% | +1.67% |
| YTD return | -26.05% | -7.58% |
| 1-year return | -5.56% | -11.59% |
| 5-year return | -99.79% | -13.48% |
| Forward P/E | — | 30.50 |
| EPS (TTM) | $-4.31 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $2.01 |
| 52-week low | $12.51 | $1.04 |
| Distance from 52-week high | -44.66% | -39.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +228.22% | +248.36% |
| Average volume | 925.93K | 10.07M |
| Shares outstanding | 53.63M | 642.47M |
| Employees | 33 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
AVTX vs GERN FAQ
Which is bigger, Avalo Therapeutics or Geron?
Geron (GERN) is larger, with a market capitalization of $783.82M compared with $720.25M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or GERN?
AVTX returned -5.56% over the past 12 months, compared with -11.59% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.